TON Strategy Co. Ordinary Shares TONX 深 沪
等待开盘 10-29 09:30:00 美东时间
4.15
+0.060
+1.47%
华盛通- 最 高4.18
- 今 开4.07
- 成交量 34.43万股
- 最 低 3.99
- 昨 收 4.09
- 总市值 2.51亿
- 52周最高 29.77
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.46
- 委 比 -41.64%
- 总股本 6053.89万
- 历史最高 29.77
- 量 比 0.51
- 振 幅 4.65%
- 历史最低 0.0407
- 每 手 1
- 风险率 3.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TON Strategy Company Holds Annual Stockholders Meeting
TON Strategy Company ( ($TONX) ) has provided an announcement. On October 24, 2...
今天 00:47
Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital
Tonix Pharmaceuticals has initiated the FOCUS study to evaluate intranasal potentiated oxytocin products (TNX-1900/TNX-2900) in patients with arginine-vasopressin deficiency (AVP-D), a rare disorder linked to oxytocin deficiency and mental health challenges. The randomized, double-blind, placebo-controlled crossover pilot trial aims to assess the effects of single and two-week doses of oxytocin on anxiety, depression, and socioemotional functioni...
10-22 11:00
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
Tonix Pharmaceuticals announced that Dr. Gregory Sullivan will present a poster on Tonmya™ (cyclobenzaprine HCl sublingual tablets) at the 2025 American College of Rheumatology Convergence in Chicago. The presentation will highlight Tonmya's effectiveness in reducing pain and its favorable tolerability in fibromyalgia patients. Tonmya is FDA-approved as a first-in-class, non-opioid treatment for fibromyalgia and is part of Tonix's pipeline target...
10-21 11:00
12 Information Technology Stocks Moving In Tuesday's After-Market Session
Gainers Sobr Safe (NASDAQ:SOBR) shares moved upwards by 6.1% to $3.6 during Tu...
10-15 05:05
Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation
Tonix Pharmaceuticals' CEO, Seth Lederman, presented on anti-CD154 monoclonal antibody immunomodulation at the Japan Society for Transplantation's annual congress. The talk highlighted TNX-1500, a third-generation monoclonal antibody targeting CD40L, with promising Phase 1 safety and biomarker data. TNX-1500 is being developed to prevent organ transplant rejection and treat autoimmune diseases. Lederman emphasized the role of T-regulatory cells, ...
10-14 11:00
TON Strategy Faces Nasdaq Compliance Challenge
TON Strategy Company ( ($TONX) ) has shared an announcement. On October 9, 2025...
10-11 05:48
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025
Tonix Pharmaceuticals Holding Corp. announced that Dr. Sina Bavari and Dr. Zeil Rosenberg will participate in the World Vaccine Congress–Europe 2025 in Amsterdam. Dr. Bavari will present on the safety and efficacy of the TNX-801 mpox vaccine, while both will engage in a panel discussion on enhancing vaccine effectiveness using mpox as a model. The event takes place October 14–16, 2025. Tonix is a biotech company advancing treatments for fibromyal...
10-09 11:00
Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026
Tonix Pharmaceuticals plans to advance TNX-2900, a magnesium-potentiated intranasal oxytocin formulation, into a Phase 2 clinical trial for children and adolescents with Prader-Willi Syndrome (PWS). TNX-2900 aims to improve receptor binding consistency and reduce off-target effects. The FDA has granted it Orphan Drug and Rare Pediatric Disease Designations, making Tonix eligible for a Priority Review Voucher upon approval. The trial will assess s...
09-29 11:00
Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Tonix Pharmaceuticals licencie le TNX-4800, un anticorps monoclonaux à longue durée d’action cible la protéine表面抗原A (OspA) de Borrelia burgdorferi responsable de la maladie de Lyme. Conçu pour une administration unique au printemps, il offre une protection tout au long de la saison des tiques. Un essai de phase 1 a confirmé la sécurité, la tolérance et une relation linéaire pharmacocinétique-pharmacodynamique-efficacité. L’objectif est de protége...
09-17 11:00
加密货币市场动态：Tether、Polymarket 等企业的新动作
1. **Tether 推出合规稳定币 USAT，前白宫官员掌舵**：全球最大稳定币 USDT 发行商 Tether 推出合规美元稳定币 USAT，由前白宫加密委员会执行董事 Bo Hines 领导，严格遵循美国《GENIUS 法案》。 2. **Polymarket 融资估值飙升，有望重返美国市场**：区块链预测平台 Polymarket 投后估值达至少 30 亿美元，计划重返美国市场，已收购衍生品交易所 QCX 并获得 CFTC 无异议函。 3. **温克莱沃斯兄弟：比特币未来十年有望达 100 万美元**：温克莱沃斯兄弟预测比特币可取代黄金，未来十年价格或达 100 万美元，强调比特币是“黄金 2.0”。 4. **SOL 财库公司 Forward Industries 大规模购入 SOL**：纳斯达克上市公司 Forward Industries 已购入 400 万枚 SOL，价值 8 亿美元，计划继续购买。 5. **WisdomTree 推出首个代币化基金**：推出代...
09-13 10:34
